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Background: The study investigated whether tumor volume changes 
at 8 weeks of therapy is associated with outcomes in advanced non–
small-cell lung cancer (NSCLC) patients harboring sensitizing epi-
dermal growth factor receptor (EGFR) mutations treated with EGFR 
tyrosine kinase inhibitors (TKIs).
Methods: In 56 advanced NSCLC patients with sensitizing EGFR 
mutations treated with first-line erlotinib or gefitinib, tumor volumes of 
dominant lung lesions were measured on baseline and follow-up com-
puted tomography, and were analyzed for association with survival.
Results: Among 56 eligible patients, the median tumor volume was 
17.8 cm3 (range, 1.3–172.7 cm3) on the baseline scans. Forty-nine 
patients had follow-up computed tomography at approximately 8 
weeks; the median tumor volume at 8 weeks was 7.1 cm3 (range, 
0.4–62.3 cm3), with the median proportional volume change of −59% 
(range, −90% to +91%) from baseline. The proportional volume 
change at 8 weeks was associated with survival (p = 0.02). Using the 
cutoff value of 38% volume decrease (75th percentile) at 8 weeks, 
patients with volume decrease more than 38% (n = 37) had a median 
overall survival of 43.5 months compared with 16.3 months among 
those with volume decrease of 38% or less (n = 12; p = 0.01). The 
median progression-free survival for patients with more than 38% 
volume decrease was 12.6 months, compared with 5.5 months for 
those with 38% or lesser volume decrease (p = 0.2).
Conclusion: The proportional volume change at 8 weeks is associ-
ated with overall survival in EGFR-mutant advanced NSCLC patients 
treated with first-line EGFR-TKIs. The observation of the study, if con-
firmed in larger study cohorts, indicates that tumor volume analysis at 
8 weeks may provide an early marker for survival, and contribute to 
therapeutic decision making by identifying patients who may benefit 
from additional anticancer therapy after 8 weeks of EGFR-TKI therapy.
Key Words: Lung cancer, Computed tomography scans, Tumor vol-
ume, Epidermal growth factor receptor mutations, Epidermal growth 
factor receptor tyrosine kinase inhibitors.
(J Thorac Oncol. 2013;8: 1059-1068)
Lung cancer is the leading cause of cancer death in the United States, accounting for more than 160,000 deaths per 
year.1,2 The epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs), erlotinib and gefitinib, are associ-
ated with a dramatic clinical response in patients with EGFR-
sensitized mutations, with response rates greater than 70%, 
and progression-free survival (PFS) of 9.7 to 13.1 months.3–9 
However, nearly all patients with initial responses eventually 
relapse because of acquired resistance to EGFR-TKIs.10–14
Medical oncologists typically rely on changes in one-
dimensional tumor size measured on computed tomography 
(CT) as the major determinant in defining tumor progression 
and deciding when to change therapy.15–17 However, based on 
increasing clinical experience, the conventional Response 
Evaluation Criteria in Solid Tumors (RECIST)– based assess-
ment alone may not be sufficient to fully characterize response 
and progression in genomically defined patients with specific 
tumor types, such as melanoma and lung cancer, receiv-
ing targeted therapies.18–21 Given the increasing understand-
ing of molecular mechanisms of non–small-cell lung cancer 
(NSCLC) in response and resistance to EGFR-TKI, additional 
radiographic strategies for objective response assessment and 
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determination of progression are needed to better guide thera-
peutic decisions in EGFR-mutant NSCLC patients.19–21
Advancement of multidetector-row CT technology has 
enabled volumetric tumor measurements, which have attracted 
attention as a method to complement limitations of conventional 
size-based criteria.22–28 Tumor volume measurement in lung 
cancer has been shown to be more reproducible than size 
measurement.22–28 We have previously established a method 
of CT tumor volume measurement of advanced NSCLC using 
clinical chest CT and commercially available Food and Drug 
Administration–approved software.28 Variability of measurements 
in advanced NSCLC was investigated, demonstrating that tumor 
volume is more reproducible than size.28
Although radiological investigations have been per-
formed to assess tumor volume changes in lung cancer,29,30 
few studies have assessed volumetric changes of advanced 
NSCLC with specific genomic mutations during targeted ther-
apy. Moreover, the association between tumor volume changes 
and survival has not been systematically studied in genomi-
cally defined NSCLC patients receiving targeted therapy.
The purpose of the present study is to determine whether 
the tumor volume changes at 8 weeks of therapy are associated 
with survival in advanced NSCLC patients harboring sensitiz-
ing EGFR mutations treated with the first-line EGFR-TKI. If 
the greater initial decrease in tumor volume is associated with 
longer survival, the decrease in tumor volume can serve as an 
early predictor of survival and help optimize the therapeutic 
approaches. An 8-week landmark was chosen because it is the 
timepoint when the first follow-up CT is performed in trials 
of EGFR-TKIs,31–33 and was used as a landmark timepoint in 
the Biomarker-integrated Approaches of Targeted Therapy for 
Lung Cancer Elimination (BATTLE) trial, where disease con-
trol at 8 weeks was the primary endpoint.34,35
PATIENTS AND METHODS
Patients
The original cohort included 101 consecutive patients, 
with stage IV NSCLC or stage I–IIIA NSCLC with systemic 
relapse and sensitizing EGFR mutations, who were treated 
with gefitinib or erlotinib as their initial systemic therapy 
for advanced NSCLC at the Dana-Farber Cancer Institute 
between February 2002 and May 2010.36,37
Baseline CT and at least one follow-up CT during 
EGFR-TKI therapy were available in 70 patients. In 29 patients 
of the remaining 31 patients, baseline and/or follow-up CT 
scans were not available in our system; these studies were per-
formed at other institutions. The remaining two patients had 
no follow-up CT during TKI therapy; one patient discontinued 
EGFR-TKI therapy at 2 weeks because of toxicity, and the 
other patient discontinued TKI at 2 weeks, and died 2 weeks 
later, because of progressive disease.
The baseline chest CT scans of the 70 patients were 
reviewed by a thoracic radiologist (MN) to identify patients 
with at least one measurable lung lesion (≥10 mm).28 Among 
70 patients, 56 patients had at least one measurable lung 
lesion. The remaining 14 patients had no measurable lung 
lesions, although they did have nonmeasurable lesions in 
the lung (such as small nodules <10 mm or effusion) and/or 
lesions outside the lungs, such as hepatic or osseous lesions. 
Therefore, the study population consisted of 56 advanced 
NSCLC patients with sensitizing EGFR mutations treated 
with first-line erlotinib or gefitinib.
Thirty patients were treated in prospective trials of 
gefitinib or erlotinib,4,31–33,38 and 26 patients were treated as 
a part of the standard clinical care. The collection of clinical 
information on patients with somatic EGFR mutations was 
approved by the Institutional Review Board.
Mutation Analysis
Tumor specimens were obtained from diagnostic or sur-
gical procedures. Samples consisted of frozen tumor speci-
mens or paraffin-embedded material. EGFR exons 18 to 21 
were amplified by polymerase chain reaction and analyzed 
bidirectionally through direct sequencing for the presence of 
somatic mutations.39–41 The following EGFR mutations were 
considered sensitizing: deletions, duplications, and deletion-
insertions of exon 19, L858R point mutation, L861Q point 
mutation, and G719 mis-sense point mutations.37,41
CT Tumor Volume and Size Measurement
Baseline and follow-up chest CT scans were performed 
to determine response to EGFR-TKI using the clinical chest 
CT protocol. The follow-up CT scans were performed after 
every 8 weeks (n = 29) or every 6 weeks (n = 1) in patients 
treated in trials, and per discretion of treating providers in 
patients treated off protocol (n = 26).
A thoracic radiologist measured the volume and size 
(the longest diameter) of a dominant measurable lung lesion 
(1 lesion per patient) on baseline and follow-up CT scans dur-
ing EGFR-TKI therapy, using Food and Drug Administratio–-
approved volume analysis software (Vitrea 2; Vital Images, 
Minnetonka, MN).28
Proportional Tumor Volume and Size 
Changes Compared with Baseline
The proportional changes of tumor volume and size at 
each follow-up were calculated. At time t(i), the tumor volume 
and size were defined as v(i) and x(i), respectively, t(0) was 
when baseline CT was obtained. At a time t(i), the percent vol-
ume and size changes (%v[i], %x[i]) compared with baseline 
volume (v[0]) and size (x[0]) were calculated:
%v(i) = (v[i] – v[0])/v(0)
%x(i) = (x[i] – x[0])/x(0)
The proportional volume and size changes at 8 weeks, 
and at the nadir (the smallest tumor volume or size from 
baseline to TKI termination), were obtained. Because not all 
patients had follow-up CT exactly at 8 weeks, 6 to 10 weeks 
were allowed for the 8-week scan. Forty-nine patients had fol-
low-up CT at 8 ± 2 weeks; the subsequent analysis at 8 weeks 
was performed in these 49 patients, excluding seven patients 
without scans at 8 ± 2 weeks.
Statistical Analysis
The association between the 8-week measure of tumor 
volume or size and outcomes was assessed using landmark 
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analyses defining 8 weeks as the landmark time. Overall 
survival (OS) was defined as the time from the date of the 
8-week follow-up scan until death from any cause. PFS was 
defined as the time from the date of the 8-week follow-up scan 
until the date of progression or death. Progression was based 
on RECIST for patients in trials, and was defined clinically for 
nontrial patients based on sufficient tumor growth, to discuss 
alteration of therapy and/or a new site of disease on imaging.21 
Patients not experiencing the event by the time of analyses were 
censored at the last known date of follow-up. The log-rank test 
was used to assess differences in the OS and PFS distributions 
between groups. Cox proportional hazards models were used 
to estimate hazard ratios (HRs), and multivariate analyses 
were performed using a stepwise regression. Differences in 
demographics and disease characteristics were tested using 
Fisher’s exact test for categorical data and Wilcoxon test for 
continuous data. All p values were two-sided at the 0.05 level 
and no adjustments were made for multiple comparisons.
RESULTS
Tumor Volume and Size at Baseline 
and during EGFR-TKI Therapy
Table 1 summarizes the demographics and disease char-
acteristics of the 56 patients. The median follow-up time from 
the initiation of EGFR-TKI was 35.2 months.
The median baseline tumor volume was 17.8 cm3 (range, 
1.3–172.7 cm3), 7.7 cm3 (range, 0.4–62.3 cm3) at 8 weeks of 
therapy, and 4.8 cm3 (range, 0.2–62.3 cm3) at nadir. The median 
time from the initiation of TKI to nadir volume was 5.5 months. 
The median proportional volume change at 8 weeks was −59% 
(range, −90 to +91%). The proportional volume change at nadir 
had a median of −71% (range, −99% to 0%). The tumor volume 
continued to increase throughout therapy in two patients, whose 
nadir volume was at baseline. A representative tumor volume 
change during TKI therapy is shown in Figure. 1.
The median baseline tumor size was 3.7 cm (range, 
1.2–9.1 cm), 2.8 cm (0.9–9.0 cm) at 8 weeks, and 2.0 cm (0.7–
8.4 cm) at nadir. The median time from the initiation of therapy 
to nadir size was 5.0 months. The median proportional change 
in size at 8 weeks was −22% (range, −69% to +50%); the pro-
portional size change at nadir had a median of −40% (range, 
−81% to 0%). The tumor size continued to increase throughout 
therapy in five patients, whose nadir size was at baseline.
Association between Tumor Volume 
and Size Versus Survival
At baseline
Neither baseline volume nor size was a predictor of OS 
or PFS when fitted as continuous variables in the Cox mod-
els (OS, p = 0.57, 0.50, respectively; PFS, p = 0.84, 0.57, 
respectively).
At 8 weeks of therapy
In 49 patients with 8-week scan, the proportional vol-
ume decrease at 8 weeks had significant association with 
OS, when fitted as a continuous variable in a Cox model (p = 
0.02). The association was further explored by categorizing 
patients according to the 8-week volume decrease and by plot-
ting Kaplan–Meier curves. When patients were categorized 
into four groups using the quartiles (−66%, −59%, −38%), 
the group with the least volume decrease had the shortest OS 
(10 deaths among 12 patients; the median OS 16.3 months; 
95% confidence interval [CI] for the median: 13.0 months-not 
reached), whereas OS was longer in groups with greater vol-
ume decrease (Figs. 2 and 3).
After visual inspection of the Kaplan–Meier estimates 
of the OS distribution, we proposed that dichotomizing the 
patients into those with more than 38% volume decrease 
versus those with less than or equal to 38% volume decrease 
may serve as an appropriate cutpoint. This cutpoint was further 
studied using a recursive partitioning model. Patients with 
volume decrease more than 38% (n = 37) had significantly 
longer OS (median OS, 43.5 months; 95%CI for the median: 
29.1 months-NR) compared with those with volume decrease 
less than or equal to 38% (n = 12; median OS: 16.3 months; 
p = 0.01) (Figs. 4 and 5). The median PFS for patients with 
more than 38% volume decrease was 12.6 months (95% 
TABLE 1.  Patient Demographics and Disease Characteristics 
of 56 Patients
Variables Category Total (N = 56)
Sex Female 48 (86)
Male 8 (14)
Age yr Median (range) 63 (35–84)
Race White 50 (89)
Asian 4 (7)
Black 2 (4)
Smoking statusa Never 26 (46)
Former 28 (50)
Current 2 (4)
Pathology Adenocarcinoma 49 (88)
NSCLC NOS 7 (12)
ECOG PS 0 22 (39)
1 31 (55)
2 2 (4)
3 1 (2)
Extrathoracic metastasisb Present 32 (57)
Absent 24 (43)
EGFR-TKI Erlotinib 51 (91)
Gefitinib 5 (9)
Sensitizing EGFR mutations Exon 19 del 28 (50)
Exon 19 del and L861Q 1 (2)
L858R 19 (34)
L861Q 4 (7)
L861Q and G719 1 (2)
G719 3 (5)
The values in parenthesis represent percentages unless otherwise specified.
aNever: Less than 100 lifetime cigarettes; Former: quit 1 year or more before start of 
EGFR-TKI; Current: smoked 1 year or less before start of EGFR-TKI34
bExtrathoracic metastasis at diagnosis of advanced disease.
ECOG, Eastern Cooperative Oncology Group; NSCLC NOS, Non–small-cell lung 
cancer not otherwise specified; PS, performance status; EGFR, epidermal growth factor; 
TKI, tyrosine kinase inhibitor.
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CI 9.4–15.0 months), compared with 5.5 months (95% CI 
3.3-not reached) for those with less than or equal to 38% 
volume decrease (p = 0.2) (Fig. 6). Although not statistically 
significant, the longer PFS in the patients with volume decrease 
of more than 38% was consistent with the observation of 
longer survival with this degree of tumor shrinkage. Table 2 
summarizes the demographics and the disease characteristics 
of the 37 patients with more than 38% volume decrease versus 
12 patients with 38% or lesser volume decrease at 8 weeks.
Multivariable analysis was performed for OS, adjusting 
for 8-week volume decrease using the 38% cutpoint, sex, age, 
race, smoking status, pathologic type, Eastern Cooperative 
Oncology Group performance status, distant metastasis, 
and EGFR mutations. Stepwise regression was conducted, 
removing variables if they were not significant at the p value 
of 0.2. The final model was adjusted for four factors: 8-week 
volume decrease more than 38% (HR = 0.23; p = 0.002), 
distant metastasis (HR = 2.4; p = 0.05), age more than 50 years 
FIGURE 1.  A representative tumor 
volume changes during EGFR-TKI 
therapy in a 56-year-old female with 
lung adenocarcinoma harboring exon 
19 deletion treated with erlotinib. A 
significant initial volume decrease was 
noted at the 8-week scan (67% decrease 
comparing with baseline). The tumor 
volume further decreased gradually, and 
reached the nadir at 15 months with 
83% decrease compared with baseline. 
Subsequently, tumor volume gradually 
increased during TKI therapy, which was 
terminated at 51 months. EGFR-TKI, epi-
dermal growth factor receptor tyrosine 
kinase inhibitor.
FIGURE 2.  An example of marked 
proportional tumor volume decrease 
at 8 weeks associated with longer 
survival in a 54-year-old woman with 
lung adenocarcinoma harboring exon 
19 deletion treated with erlotinib. A 
and B, Baseline CT scan of the chest 
demonstrates a dominant lung mass 
in the left lower lobe, with a volume 
of 73.1 cm3. C and D, Follow-up CT 
at 8 weeks of therapy demonstrated 
marked decrease of tumor volume, 
measuring 9.9 cm3, with the pro-
portional volume change of −86% 
compared with baseline. The overall 
survival of the patient since the initia-
tion of erlotinib was 45.4 months. CT, 
computed tomography.
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(HR = 0.15; p < 0.001), and EGFR exon19 deletion (HR = 
0.28; p = 0.01).
Proportional size change at 8 weeks was not associ-
ated with OS in a Cox model (p = 0.22). When patients 
were dichotomized at the median size change of −22%, no 
significant difference was observed in OS (p = 0.11) or PFS 
(p = 0.06).
At nadir
Neither the proportional volume change at nadir, nor the 
time to nadir volume was associated with OS (p = 0.23, 0.25, 
respectively), when fitted as time-varying covariates in a Cox 
model. The tumor size change at nadir was associated with 
OS (p = 0.03), as was the time to nadir size (p = 0.04), with 
patients taking longer time to nadir having longer survival.
DISCUSSION
The present study demonstrated that proportional tumor 
volume decrease at 8 weeks of therapy was associated with 
prolonged survival in advanced NSCLC patients, with sen-
sitizing EGFR mutation treated with first-line gefitinib or 
erlotinib. To our knowledge, this is the first report demonstrat-
ing that tumor volume can serve as an early predictor of pro-
longed survival in EGFR-mutant advanced NSCLC patients 
treated with first-line EGFR-TKIs.
Increasing attempts have been made to use tumor 
volume in response assessment and provide an imaging-based 
marker for survival.25–29 Tumor volume changes after therapy 
have shown to be associated with survival in different solid 
tumors, including locally advanced rectal adenocarcinoma, 
treated with chemoradiotherapy and surgery,42 cervical cancer 
receiving radiotherapy,43 and malignant pleural mesothelioma 
treated with chemotherapy, extrapleural pneumonectomy, 
and radiation.44 In lung cancer, Zhao et al.23 reported that 
semiautomated tumor segmentation identified a larger number 
of patients with absolute tumor volume changes, compared 
with unidimensional or bidimensional techniques. The 
reproducibility of tumor volume measurements in lung cancer 
has been extensively studied, demonstrating that tumor volume 
is more reproducible than size.24,27,28 Volumetric tumor change 
during neoadjuvant gefitinib better distinguished tumors with 
sensitizing EGFR mutation compared with unidimensional 
tumor change.29
FIGURE 3.  Overall survival in four 
groups of patients categorized using 
the quartiles (−66%, −59%, −38%) of 
the proportional volume change at 8 
weeks of therapy. 
FIGURE 4.  Overall survival in patients dichotomized using 
the cutoff value of −38% volume change at 8 weeks of 
therapy.
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However, only a few reports evaluated the association 
between tumor volume and survival in NSCLC patients, 
mostly during chemotherapy plus chest radiotherapy.45–47 In 
inoperable stage I–IIIB NSCLC treated with chemotherapy 
plus chest radiotherapy, larger primary tumor volume and 
primary plus nodal tumor volume before therapy were asso-
ciated with shorter survival.45 In stage III NCSLC treated 
with concurrent chemotherapy and chest radiation, larger 
primary tumor volume and nodal volume were associated 
with shorter survival.46 In locally advanced NSCLC treated 
with trimodality therapy, larger primary tumor volume was 
associated with shorter PFS; pre- and posttreatment posi-
tron emission tomography uptake did not correlate with 
survival.47
In the present study, proportional tumor volume change 
at 8 weeks of EGFR-TKI therapy was significantly associated 
with prolonged survival. The result is similar to the report of 
malignant pleural mesothelioma, which demonstrated that 
percentage of change in tumor volume after two cycles of 
chemotherapy was associated with OS (HR: 1.94; p = 0.04).44 
Furthermore, 8-week volume decrease remained significant 
after adjusting for other factors. Our results indicate that 
tumor volume change can be an early predictor of survival 
in EGFR-mutant NSCLC treated with first-line EGFR-TKIs. 
Further investigation to establish volumetric response criteria 
is needed to better guide treatment decisions in patients with 
sensitizing EGFR mutation.
The cutoff value of 8-week volume change that best dif-
ferentiated the survival duration in our patients was −38%. In 
our previous study using the same technique, the 95% limits 
of agreements for volume measurements were −26.0% and 
18.6%28; −38% is beyond this range, and therefore, likely 
reflects true change rather than measurement variability. The 
cutoff values of tumor volume change predicting outcome 
differ significantly among different tumor types, stages, and 
treatments. In rectal cancer receiving preoperative chemother-
apy and radiation, patients with 70% or more of tumor volume 
reduction had longer disease-free survival.42 In mesothelioma, 
tumor volume increase versus decrease after chemotherapy 
differentiated patients with shorter and longer survival.44 
It seems that the cutoff values are specific to tumor types 
and therapeutic regimen. The cutoff value of 38% volume 
decrease, determined by using recursive partition analysis in 
the present study, needs to be validated. We propose tumor 
volume change of −38% as an initial value for validation in 
a larger independent cohort of sensitizing EGFR-mutant 
NSCLC treated with EGFR-TKI, which is the next important 
step to establish practical volumetric response criteria.
The 12 patients with 8-week volume decrease of 38% 
or lesser had significantly shorter survival. These 12 patients 
were significantly older, more frequent smokers, and had 
NSCLC not otherwise specified. Four of the 12 patients with 
38% or lesser volume decrease had an L861Q mutation. It 
may be worthwhile to further investigate detailed clinical and 
FIGURE 5.  Waterfall plot demonstrating the proportional volume change at 8 weeks in 49 patients. OS was significantly longer 
in patients with more than 38% volume decrease at 8 weeks (n = 37; light gray bars) than in patients with volume decrease at 
38% or lesser (n = 12; dark gray bars) (median OS: 43.5 months versus 16.3 months, respectively.). OS, overall survival.
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genomic characteristics of tumors between groups divided 
by volume change in a larger population, to understand the 
differences in response to EGFR-TKI among EGFR-mutant 
NSCLC patients.
The longer survival is likely related to the therapeutic 
benefit of the EGFR-TKI administered to these patients with 
sensitizing mutations of EGFR. Median PFS was longer in 
the 38% or more volume decrease group than the other group 
(12.6 versus 5.5 months), demonstrating a similar trend as in 
OS, though statistically nonsignificant. Because radiographic 
tumor increase is one of the determinants of progression, 
tumor volume change and PFS may not be independent of 
each other. OS may be a more objective measure of outcome 
for the purpose of the study.
Eight-week size changes were not associated with sur-
vival, which is consistent with earlier reports.47,48 We did not 
explore further the cutpoints for size, because (1) size was 
not a significant predictor in a Cox model; (2) 95% limits of 
agreement for size were −23.1% and 24.4% from our earlier 
study,28 and (3) other cutpoints such as the 75th percentile of 
size change (−12%), or the size change equivalent to −38% 
volume change (−15%, based on a mathematical conversion 
proposed in RECIST)15 were within the range of measurement 
error, and therefore, could not be used reliably. In addition, 
our objective was not to compare volume and size; each mea-
sure has its advantages and disadvantages, and should be used 
jointly to aid therapeutic decisions in clinical practice.
Baseline tumor volume or size did not correlate with 
survival. The result is somewhat counterintuitive, because the 
baseline tumor volume and size are considered as functions of 
the T status of the tumor, node, metastasis staging, which is 
associated with OS in NSCLC patient population in general. 
In the cohorts of NSCLC patients (stage I–IIIB in one study, 
and stage III in the other) treated with chemotherapy plus chest 
radiation, baseline primary tumor volume was associated with 
survival.45,46 The result of the present study can be because 
of a small sample size with advanced-disease patients alone, 
and can also be because of a specific cohort of a genomically 
selected NSCLC patients, harboring sensitizing EGFR muta-
tions, who demonstrated dramatic initial tumor shrinkage with 
a volumetric response (median change of −59%) to EGFR-
TKIs. Association between tumor volume and survival seems 
to be dependent on cohorts and treatments given.
Neither the volume change at the nadir, nor the time 
to nadir volume was associated with survival. The results do 
not discourage the attempts to use tumor volume in response 
assessment; the nadir can only be determined retrospectively 
after completing tumor measurements until therapy 
termination, and therefore, cannot serve as a useful marker 
to guide therapeutic options in patients with ongoing therapy. 
We observed that nadir size and time to nadir size were 
associated with survival. However, with a small sample size 
and a relatively low event rate, these results may be skewed 
by outliers.
The study has several limitations, including a retro-
spective design and a small number of patients treated at a 
single institution. Although 101 patients met oncologic eli-
gibility criteria, only 49 patients were eligible for 8-week 
volume analysis, and others were excluded because of non-
availability of CT scans (n = 31), lack of measurable lung 
lesions (n = 14), and lack of 8-week scans (n = 7). The volu-
metric analysis requires the actual CT data, which are not 
always available in patients scanned at other institutions. 
Our cohort of 49 patients is larger than that in most pre-
vious volumetric studies of NSCLC,23,24,28,29,47,48 and is the 
first genomically defined cohort of EGFR-mutant NSCLC 
patients whose tumor volume and survival were analyzed. 
We are planning to further expand the cohort, by identifying 
more patients and by obtaining outside scans, and assess the 
validity of the 38% cutpoint.
Tumor volume measurement included one dominant 
lung lesion per patient, and smaller lung lesions or extrapul-
monary lesions were not taken into account. We chose this 
approach because we believe that tumor volume analysis 
should be additive to RECIST, which is simple and practical, 
and designed to evaluate systemic tumor burden.19 The single 
lesion approach is usually used in studies of response assess-
ment in NSCLC using advanced imaging techniques.50–53 
Several reports demonstrated that reducing the number of tar-
get lesions does not affect response assessment by RECIST in 
NSCLC and other malignancies54,55; the single largest lesion 
measurement yielded the same treatment-response classifica-
tion as measuring up to five lesions in more than 90% of meta-
static colon cancer patients treated in a phase 3 trial.54 In our 
cohort of 49 patients, RECIST1.1 assessment has been per-
formed as a part of our previous study,21 and 48 patients dem-
onstrated partial response (n = 28) or SD (n = 20) at 8 weeks. 
One patient had progressive disease at 8 weeks because of a 
new lung nodule, whereas target lesions had no significant 
change. The 8-week volume decrease of this patient was less 
FIGURE 6.  Progression-free survival in patients dichoto-
mized using the cutoff value of −38% volume change at 8 
weeks of therapy.
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than 38% cutpoint. It should be noted that the results of tumor 
volume analysis of one representative lung lesion need to be 
interpreted in conjunction with the RECIST-based assessment 
to capture the systematic tumoral behavior.
In conclusion, proportional tumor volume decrease at 
8 weeks of EGFR-TKI therapy predicted OS in advanced 
NSCLC patients with sensitizing EGFR mutation. Further 
investigation is warranted to validate the observation and 
establish volumetric criteria of response assessment to bet-
ter guide therapeutic decisions in this genomically defined 
subset of NSCLC patients. If the observation of the study is 
reproduced in larger study cohorts, tumor volume analysis at 
8 weeks of EGFR-TKI therapy may serve as an early objec-
tive marker of survival in advanced NSCLC patients harbor-
ing EGFR-sensitized mutations, and help identifying patients 
who may benefit from additional therapy in therapeutic deci-
sions after 8 weeks of EGFR-TKI therapy.
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